Investors

  1. BioGaia
  2. Investors

Interim report Q3 2018

Download the BioGaia Interim report January 1 – September 30 2018, released October 24 2018 (577 KB). Download here

Telephone conference Q3 2018

Acting Managing Director BioGaia, Sebastian Schröder, comments on Interim report Q3 2018. Listen here

 

The class B shares of BioGaia AB are listed on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. See share information from OMX Nasdaq Stockholm. Read more

 

BioGaia annual report

Download BioGaia annual report for the financial year 2017. Download

 

Investor presentation

Here you can download BioGaia's latest investor presentation from November 2018 Download

Financial reports

Here you will find all information related to BioGaia's financial reports.

Read more

Press releases

Here you will find all our press releases and news.

Read more

Financial calender

Keep up to date with key investor events via our financial calendar.

Read more

Subscribe to our press releases

Be the first to know all about the latest news from BioGaia. Subscribe here

 

 

Investor contact

Margareta Hagman, CFO

Phone: +46 (0)8 555 293 04
Mobile: +46 (0)708 72 82 33
E-mail: mh@biogaia.se

Analysts covering BioGaia

Carnegie, Kristofer Liljeberg
SEB, Richard Koch
Danske Bank, Daniel Albin

Read more

Our business model

Thanks to a successful business model, BioGaia has been able to grow globally with a lean, efficient and agile organization.

Read more

Mission and vision

BioGaia performs research and development to provide consumers with clinically effective, healthful, patented and user friendly probiotic products. BioGaia aim to be the groundbreaking leader in probiotics through...

Read more

About BioGaia

BioGaia is an innovative Swedish health care company and a world leader in probiotics with more than 25 years experience of developing, marketing and selling probiotic products.

Read more

We use cookies to make your experience of our website better. Using this website means you are OK with this. Find out more.

I acknowledge and accept